These estimates are clearly higher than the generally accepted low risk of local failure for patients without BRCA1/2 variants.27 These findings are further supported by a meta-analysis by Valachis et al,28 who reported a higher risk of ipsilateral breast cancer recurrence among variant carriers compared with noncarriers. The gene discussed is BRCA1; the disease is breast carcinoma.